Jennifer Pfiffer is 52 years old and is about to commence treatment with the alkylating agent cisplatin for bladder cancer. It is anticipated that she will develop severe neutropenia during therapy and so she will be treated with the granulocyte colony-stimulating factor (G-CSF) filgrastim. What patient education will you offer Jennifer regarding the effects of neutropenia? A common adverse effect associated with filgrastim therapy is bone pain. How should this be controlled?